Literature DB >> 7509872

Enzyme selectivity analyses of arylsulfonylamino acid aldose reductase inhibitors.

R A Davis1, C A Mayfield, J L Aull, J DeRuiter.   

Abstract

Arylsulfonylamino acids, displaying a wide range of inhibitory activities versus rat lens aldose reductase (RLAR), were analyzed for enzyme selectivity in several test systems. These RLAR inhibitors were found not to produce significant inhibition of genetically-linked reductases (aldehyde reductase, ALR), catalytically similar reductases (Pachysolen tannophilus xylose reductase, PTXR), functionally distinct oxidoreductases (glutathione reductase, GR, lactate dehydrogenase, LDH, and gamma-transaminase, GABA-T), and thymidylate synthase (TS). These data suggest that aldose reductase differs significantly from other oxidoreductases in its inhibitor binding domain(s). Furthermore, the aldose reductase selectivity demonstrated by the arylsulfonylamino acids suggests that these compounds may not inhibit other key metabolic transformations in various cell types and that they may function as selective probes for studies of the relationship between aldose reductase mediated biochemical changes and the pathologies of chronic diabetes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7509872     DOI: 10.3109/14756369309040751

Source DB:  PubMed          Journal:  J Enzyme Inhib        ISSN: 1026-5457


  3 in total

1.  A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications.

Authors:  Jithan V Aukunuru; Gangadhar Sunkara; Surya P Ayalasomayajula; Jack DeRuiter; Randall C Clark; Uday B Kompella
Journal:  Pharm Res       Date:  2002-03       Impact factor: 4.200

2.  Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor.

Authors:  Gangadhar Sunkara; Surya P Ayalasomayajula; Jack DeRuiter; Uday B Kompella
Journal:  Brain Res Bull       Date:  2009-09-15       Impact factor: 4.077

3.  Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor.

Authors:  Gangadhar Sunkara; Surya P Ayalasomayajula; Cheruku S Rao; Jonathan L Vennerstrom; Jack DeRuiter; Uday B Kompella
Journal:  J Pharm Pharmacol       Date:  2004-03       Impact factor: 3.765

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.